Header Logo

Connection

JORGE CASTILLO to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Follow-Up Studies.
JORGE CASTILLO
Connection Strength
0.827
Follow-Up Studies
  1. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.090
  2. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr?m macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
    View in: PubMed
    Score: 0.090
  3. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.086
  4. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.086
  5. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
    View in: PubMed
    Score: 0.077
  6. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97.
    View in: PubMed
    Score: 0.067
  7. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.058
  8. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9.
    View in: PubMed
    Score: 0.055
  9. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010 Oct; 51(10):1822-8.
    View in: PubMed
    Score: 0.045
  10. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.024
  11. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.023
  12. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558.
    View in: PubMed
    Score: 0.020
  13. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
    View in: PubMed
    Score: 0.020
  14. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.020
  15. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
    View in: PubMed
    Score: 0.019
  16. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.017
  17. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015 Apr; 39(4):400-5.
    View in: PubMed
    Score: 0.015
  18. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.